Michael Mosley's family say 'it's been hardest year' as anniversary marked
The family of Michael Mosley has paid tribute to him on the first anniversary of his passing, describing the past year as "has been the hardest of our lives".
Mosley, who passed away at the age of 67 while holidaying with his wife Dr Clare Bailey Mosley on the Greek island of Symi last year, was renowned for popularising diets and presenting science programmes.
His wife posted on Instagram: "It's hard to believe that a year has passed since we lost Michael. Not a day goes by without thinking of him – his warmth, his laughter, his endless curiosity about the world, and his deep love for our family.
"This past year has been the hardest of our lives. Navigating the loss of someone so central to our hearts and our home has changed everything. We have missed him in the big moments and the small ones. But we have also felt incredibly supported.
"The outpouring of love, stories and memories from so many of you has meant more than we can ever say. We have taken real comfort in knowing just how many lives Michael touched – not only through his work, but through his kindness, humour, and deep desire to help people live well for longer."
The message expressed gratitude to "everyone who has reached out, shared their grief, and carried us with their compassion, thank you. Your messages, letters and acts of remembrance have helped us through the darkest days".
The statement continued: "We are trying, as a family to look forward. To carry on the work Michael was so passionate about. To live with purpose and joy, as he would have wanted us to. With love and deepest gratitude, Clare and the Mosley family."
In a touching tribute to his legacy, last month the family launched a research initiative in his name, revealing that a new clinical research fellowship will be created in collaboration with King's College London and the Chronic Disease Research Foundation (CDRF) to enhance the country's metabolic health.
The Mosleys have joined forces with King's College London and the CDRF, who will oversee the Michael Mosley Memorial Research Fund, in their search for a committed research scientist.
Dr Mosley, celebrated for presenting BBC and Channel 4 documentaries on health and nutrition, brought the 5:2 diet, a variant of intermittent fasting, into the limelight with his book 'The Fast Diet'.
His son, Dr Jack Mosley, a GP registrar who has investigated GLP-1 drug brands such as Ozempic, Wegovy, Mounjaro, and Zepbound alongside his father, has penned a book entitled 'Food Noise: How Weight Loss Medication And Smart Nutrition Can Silence Your Cravings'.
In December, an inquest concluded that the cause of Dr Mosley's death remained "indeterminate" and "unascertainable", suggesting that it "was most likely attributable either to heatstroke (accidental) or non-identified pathological cause".
Dr Mosley had also been the voice behind BBC Radio 4's 'Just One Thing', and the BBC series 'Trust Me, I'm A Doctor', which delved into healthcare practices in Britain.
He was known for pushing the limits of his own body during numerous broadcasts, including a 2014 documentary where he swallowed tapeworms for six weeks.
In a 2015 feature, he went to great lengths to demonstrate the nutritional value of blood by making two black puddings from his own.
In July 2024, the BBC celebrated the doctor-turned-television presenter with a special day in his honour, encouraging presenters and viewers alike to take up "just one thing" to boost their health.
His wife, Clare, graciously accepted the Hall of Fame Award on his behalf at the British Podcast Awards in September 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
2 hours ago
- Scottish Sun
The most common side effects of different fat jabs revealed – as researchers find vomiting and nausea top symptom
But health officials warn fat jabs are not a silver bullet and can come with some serious side effects WEIGHT UP The most common side effects of different fat jabs revealed – as researchers find vomiting and nausea top symptom Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs do often sound like a magical quick fix to overeating and demanding hunger pangs. But the drugs can leave some users feeling seriously unwell and many in hospital. Sign up for Scottish Sun newsletter Sign up 2 Monitoring Facebook posts could be a useful way to spot side effects that might be unknown, scientists say (Credit: Getty) After scouring social media, scientists have found the most common side effects of the popular fat-busting meds. Vomiting, nausea and headaches are the most talked-about side effects of the jabs, according to the new study, which analysed thousands of Facebook posts. The US researchers looked at how people in the US were discussing GLP-1 drugs like Wegovy, Ozempic, and Mounjaro on public pages. They found that gut issues were the most frequently mentioned side effects overall, especially among users of semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Mounjaro). Mental health concerns like anxiety and depression were also raised, but far less frequently. The study, published in JMIR Infodemiology, found that vomiting was most often mentioned in posts about Mounjaro, at 3.8 per cent. Meanwhile, Wegovy users mentioned depression more than any other group, with 1.57 per cent of posts referencing the symptom. The drugs, originally developed for type 2 diabetes, have soared in popularity thanks to their dramatic weight-loss effects, with celebs like Oprah Winfrey and Sharon Osbourne singing their praises. But they've also been linked to less glamorous side effects, such as joint pain, fatigue, hair loss, and in some cases, gallbladder problems. Despite the risks, experts say the drugs are still safe and effective for most patients. Weight Loss Jabs - Pros vs Cons They help control blood sugar, trigger rapid weight loss, and cut the risk of dying from heart disease by around a fifth in people with obesity or type 2 diabetes. Roughly 1.5million people in the UK are now taking GLP-1 drugs, which have been hailed by some as game-changers in the fight against obesity. In the US, this number is even higher, with over 2 per cent of the population, approximately 4 million people, currently using these medications for weight loss. But health officials warn they are not a silver bullet and can come with side effects. The scientists found these effects varied by brand. Zepbound, a newer tirzepatide drug which is approved in the US but not the UK, was linked more often to high blood pressure, While Ozempic posts mentioned gallbladder issues most. Ozempic is approved for weight loss in the US but is only approved for diabetes in the UK. Scientists from the University of Maryland, who are behind the study, analysed nearly 60,000 unique public Facebook posts uploaded by US users of the medicines between 2022 and 2024, They used cluster analysis to map out which symptoms were often mentioned together. They found that vomiting, nausea and pancreatitis - a condition where the pancreas becomes inflamed - often came hand in hand, while anxiety frequently appeared alongside depression and fatigue. Posts about side effects spiked after major events including the US Food and Drug Administration approving Wegovy for teens, celebrity endorsements, and wider insurance coverage in the US. 2 Despite these increases, the proportion of people talking about side effects actually dropped over time. Scientists say monitoring social media could be a useful way to spot side effects that might be missed or underreported in clinical trials. But they warned that Facebook posts don't tell the full story as symptoms were self-reported, which means they can be exaggerated or incomplete. There is also no way to verify dosage, how long people were on the drugs, or even whether they were using genuine products.
The Sun
2 hours ago
- The Sun
The most common side effects of different fat jabs revealed – as researchers find vomiting and nausea top symptom
FAT jabs do often sound like a magical quick fix to overeating and demanding hunger pangs. But the drugs can leave some users feeling seriously unwell and many in hospital. 2 After scouring social media, scientists have found the most common side effects of the popular fat-busting meds. Vomiting, nausea and headaches are the most talked-about side effects of the jabs, according to the new study, which analysed thousands of Facebook posts. The US researchers looked at how people in the US were discussing GLP-1 drugs like Wegovy, Ozempic, and Mounjaro on public pages. They found that gut issues were the most frequently mentioned side effects overall, especially among users of semaglutide (the active ingredient in Wegovy) and tirzepatide (the active ingredient in Mounjaro). Mental health concerns like anxiety and depression were also raised, but far less frequently. The study, published in JMIR Infodemiology, found that vomiting was most often mentioned in posts about Mounjaro, a drug containing tirzepatide, at 3.8 per cent. Meanwhile, Wegovy users mentioned depression more than any other group, with 1.57 per cent of posts referencing the symptom. The drugs, originally developed for type 2 diabetes, have soared in popularity thanks to their dramatic weight-loss effects, with celebs like Oprah Winfrey and Sharon Osbourne singing their praises. But they've also been linked to less glamorous side effects, such as joint pain, fatigue, hair loss, and in some cases, gallbladder problems. Despite the risks, experts say the drugs are still safe and effective for most patients. Weight Loss Jabs - Pros vs Cons They help control blood sugar, trigger rapid weight loss, and cut the risk of dying from heart disease by around a fifth in people with obesity or type 2 diabetes. Roughly 1.5million people in the UK are now taking GLP-1 drugs, which have been hailed by some as game-changers in the fight against obesity. In the US, this number is even higher, with over 2 per cent of the population, approximately 4 million people, currently using these medications for weight loss. But health officials warn they are not a silver bullet and can come with side effects. The scientists found these effects varied by brand. Zepbound, a newer tirzepatide drug which is approved in the US but not the UK, was linked more often to high blood pressure, While Ozempic posts mentioned gallbladder issues most. Ozempic is approved for weight loss in the US but is only approved for diabetes in the UK. Scientists from the University of Maryland, who are behind the study, analysed nearly 60,000 unique public Facebook posts uploaded by US users of the medicines between 2022 and 2024, They used cluster analysis to map out which symptoms were often mentioned together. They found that vomiting, nausea and pancreatitis - a condition where the pancreas becomes inflamed - often came hand in hand, while anxiety frequently appeared alongside depression and fatigue. Posts about side effects spiked after major events including the US Food and Drug Administration approving Wegovy for teens, celebrity endorsements, and wider insurance coverage in the US. 2 Despite these increases, the proportion of people talking about side effects actually dropped over time. Scientists say monitoring social media could be a useful way to spot side effects that might be missed or underreported in clinical trials. But they warned that Facebook posts don't tell the full story as symptoms were self-reported, which means they can be exaggerated or incomplete. There is also no way to verify dosage, how long people were on the drugs, or even whether they were using genuine products. However, the findings offer insight into what real-world users are experiencing, beyond the controlled world of clinical trials. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Telegraph
7 hours ago
- Telegraph
Third of young people want fat jabs as demand spirals
A third of young adults want to take fat jabs amid a surge in demand for the drugs, pharmacists have said. One in five people say they have tried to access a pharmacy weight-loss treatment in the past year but this figure is 35 per cent for those aged between 16 and 34. Pharmacists have raised the alarm that demand has far exceeded what can be clinically delivered. Concerns have also been raised that people could resort to looking for drugs such as Wegovy and Mounjaro from online sellers. Current guidelines state that patients being prescribed Mounjaro and Wegovy through pharmacies need a BMI of at least 35 and at least one weight-related comorbidity, such as diabetes, to be eligible. Wegovy can also be prescribed to patients with a BMI of 30–34 who meet the criteria for referral to specialist overweight and obesity management services. However, the NHS is only rolling out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities. It spent £269million on fat jabs in 2024-2025 and prescriptions doubled to almost three million a year. Mounjaro, regarded as the strongest jab and known as King Kong, has driven the spike in prescriptions with 1.1million given out in a year compared with 3,300 in the previous 12 months. The National Pharmacy Association (NPA), which represents about 6,000 pharmacies, surveyed 2,000 Britons and found evidence of demand beyond what the NHS can offer. It is now seeking greater clarity on how pharmacies will be further involved in the distribution of weight-loss medication, something laid out in the Government's recent 10 Year Health Plan. Olivier Picard, chairman of the NPA, said: 'Weight-loss jabs are one of the biggest drug innovations this century but growing demand highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight-loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from medication. 'We're also urging the Government to bring forward plans to include pharmacies in the rollout of their NHS weight-management programme. 'Pharmacists are experts in medication and many have extensive experience delivering weight-loss injections as part of a package of care including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS and help people make the best use of these powerful medicines,' he added
